Bio-Rad’s $24 Million Patent Win Affirmed Despite Retrial Order (1)

Aug. 3, 2020, 5:53 PM; Updated: Aug. 3, 2020, 8:18 PM

The Federal Circuit on Monday sent back Bio-Rad Laboratories Inc.'s win on two of its three patent infringement claims against 10X Genomics Inc. over gene-research technology, but left its nearly $24 million damages award intact.

The ruling affirms part of a victory for Bio-Rad in the U.S. District Court for the District of Delaware against 10X Genomics—which was created by former Bio-Rad employees—over Bio-Rad’s “Droplet Digital” technology. The technology is used to split biological samples into “microdroplets” that allow researchers to create large numbers of samples with minimal handling and a small overall volume.

Bio-Rad has also sued 10X for ...

To read the full article log in. To learn more about a subscription click here.